Perspective Therapeutics (CATX) Gross Profit (2010 - 2023)

Perspective Therapeutics has disclosed Gross Profit across 14 years of filings, most recently posting -$39000.0 for Q4 2023.

• In Q4 2023, Gross Profit changed N/A year-over-year to -$39000.0; the TTM figure through Dec 2023 stood at $1.4 million (down 78.24% YoY), while the FY2024 annual figure was $614000.0, down 57.18% from the prior year.
• Gross Profit came in at -$39000.0 for Q4 2023 at Perspective Therapeutics, down from $738000.0 in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $2.8 million in Q3 2022 to a low of -$39000.0 in Q4 2023.
• Average Gross Profit over 5 years is $1.2 million, with a median of $1.2 million recorded in 2020.
• Year-over-year, Gross Profit surged 170.26% in 2022 and sank 89.52% in 2023.
• Over 5 years, Gross Profit stood at $1.1 million in 2019, then climbed by 5.04% to $1.2 million in 2020, then gained by 4.54% to $1.2 million in 2021, then jumped by 127.95% to $2.8 million in 2022, then tumbled by 101.4% to -$39000.0 in 2023.
• Per Business Quant data, the three most recent Gross Profit figures were -$39000.0 in Q4 2023, $738000.0 in Q3 2023, and $248000.0 in Q2 2023.